ND 420
Alternative Names: ND-420Latest Information Update: 30 Oct 2021
At a glance
- Originator Nang Kuang Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Oesophageal cancer
Most Recent Events
- 28 Mar 2017 Nang Kuang Pharmaceutical terminates phase II trial in Oesophageal cancer (Combination therapy, Neoadjuvant therapy) in Taiwan (NCT02017600)
- 02 Mar 2016 No development reported - Phase-II for Oesophageal cancer (Combination therapy, Neoadjuvant therapy) in Taiwan (unspecified route)
- 31 Aug 2013 Phase-II clinical trials in Oesophageal cancer (combination neoadjuvant therapy) in Taiwan (unspecified route)